Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 7/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25251094 | 0.91 | KDR (0.40) | KDRPDGFRAMET | |
| SCHEMBL25243884 | 0.90 | MET (0.37) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL25793115 | 0.90 | KDR (0.43) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL25793364 | 0.86 | MET (0.34) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL25285836 | 0.86 | BRAF (0.42) | KDRPDGFRAKITBRAFFLT1 | |
| SCHEMBL25293629 | 0.86 | KDR (0.43) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL25238455 | 0.85 | BRAF (0.39) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL29821745 | 0.85 | MET (0.37) | KDRKITAXLMET | |
| SCHEMBL25244861 | 0.84 | RET (0.40) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL25290554 | 0.84 | MET (0.44) | KDRAXLMETFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400551-A1 | NEK7 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KDR 4751/4885PDGFRA 4803/4885KIT 4277/4885 |
| US-20240400551-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | KDR 4456/4885PDGFRA 3901/4885KIT 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.